Telemedicine-Delivered Buprenorphine Treatment in the Age of COVID-19 2024 On-Demand-Presentation

Video Transcription

Video Summary

In this webinar, Dr. Felipe Castillo discussed the shifting landscape of treating opioid use disorder (OUD) post-COVID-19 pandemic. The presentation covered the advantages and considerations of telemedicine in treating OUD, key regulations, and adaptive practices. Dr. Castillo emphasized the need to recognize the emerging status quo and explore clinical considerations of telemedicine. The session included interactive discussions on adapting to virtual care, patient cases, and medication adherence monitoring. Participants engaged in analyzing scenarios involving stable versus new patients, return to substance use, and the limitations of virtual care for certain treatments like long-acting injectables. Attendees highlighted considerations including separating substance use disorders, maximizing social distancing, and incorporating off-label medications like topiramate and bupropion. The session underscored the importance of patient-centered care, regular follow-ups, and accessing resources like mentoring programs and discussion forums for ongoing support. The presentation concluded with a call to action for participants to engage with post-event evaluations to receive CME credit certificates.

Keywords

opioid use disorder

fentanyl

evidence-based practices

overdose fatalities

pharmacokinetic

pharmacodynamic

buprenorphine

naltrexone

treatment outcomes

clinical observations

webinar

Dr. Felipe Castillo

OUD

telemedicine

COVID-19 pandemic

regulations

clinical considerations

virtual care

medication adherence monitoring